Next Article in Journal
Outpatient Antibiotic Prescriptions in Pregnant Women in Małopolska Province
Next Article in Special Issue
Next Generation Sequencing for the Prediction of the Antibiotic Resistance in Helicobacter pylori: A Literature Review
Previous Article in Journal
Cranberry Extract for Symptoms of Acute, Uncomplicated Urinary Tract Infection: A Systematic Review
antibiotics-logo
Article Menu

Article Menu

Article

European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain

1
Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid (UAM) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 28006 Madrid, Spain
2
Digestive Unit, Agencia Sanitaria Costa del Sol, Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), 29651 Marbella, Spain
3
Department of Gastroenterology, Hospital de Valme, 41014 Sevilla, Spain
4
Department of Gastroenterology, Hospital Donostia/Instituto Biodonostia and CIBERehd, Universidad del País Vasco (UPV/EHU), 20014 San Sebastián, Spain
5
Department of Gastroenterology, Hospital General de Tomelloso and CIBERehd, 13700 Ciudad Real, Spain
6
Gastroenterology Unit, Hospital Central de Asturias, 33011 Oviedo, Spain
7
Gastroenterology Unit, Consorcio Hospital General Universitario de Valencia, 46014 Valencia, Spain
8
Digestive Service, HM Sanchinarro, 28050 Madrid, Spain
9
Department of Gastroenterology, Hospital San Pedro de Alcántara and CIBERehd, 10003 Cáceres, Spain
10
Department of Gastroenterology, Hospital Universitario Río Hortega, 47012 Valladolid, Spain
11
Digestive Service, Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain
12
Digestive Service, Hospital Clínico Universitario Lozano Blesa and CIBERehd, 50009 Zaragoza, Spain
13
Gastroenterology Unit, Hospital Quirón Marbella, 29603 Málaga, Spain
14
Digestive Service, Hospital General San Jorge, 22004 Huesca, Spain
15
Digestive Service, Hospital Universitari y Politècnic La Fe de Valencia and CIBERehd, 46026 Valencia, Spain
16
Digestive Service, Hospital Universitario Virgen Macarena, 41009 Sevilla, Spain
17
Digestive Service, Hospital Universitari General de Castelló, 12004 Castellón, Spain
18
Digestive Service, Hospital Universitari de Bellvitge, 08907 Barcelona, Spain
19
Digestive Service, Hospital Universitario Sanitas La Moraleja, 28050 Madrid, Spain
20
Digestive Service, Consorci Sanitari de Terrassa, 08191 Barcelona, Spain
21
Digestive Service, Complejo Asistencial Universitario de Burgos, 09006 Burgos, Spain
22
Digestive Service, Hospital Sierrallana, 39300 Cantabria, Spain
23
Digestive Service, Hospital de Cabueñes, 33394 Asturias, Spain
24
Digestive Service, Hospital de Galdakao-Usansolo, 48960 Vizcaya, Spain
25
Digestive Service, Hospital Comarcal de Inca, 07300 Mallorca, Spain
26
Digestive Service, Hospital de Mérida, 06800 Badajoz, Spain
27
Digestive Medicine Department, Hospital Clínic Universitari de Vàlencia, 46010 Valencia, Spain
28
Digestive Service, Hospital de Viladecans, 08840 Barcelona, Spain
29
Digestive Service, Clínica San Francisco, 10002 Cáceres, Spain
30
Digestive Service, Hospital Reina Sofía, Tudela, 31500 Navarra, Spain
31
Digestive Service, Hospital de Barbastro, 22300 Huesca, Spain
32
Digestive Service, Hospital Infanta Sofía, 28703 Madrid, Spain
33
Digestive Service, Hospital Universitario General de Catalunya, 08195 Barcelona, Spain
34
Digestive Service, Hospital Universitario de Fuenlabrada, idiPAZ, 28942 Madrid, Spain
35
Digestive Service, Hospital Alto del Guadalquivir, 23740 Jaén, Spain
36
Digestive Service, Hospital de Mataró, 08304 Barcelona, Spain
37
Digestive Service, Centro Universitario de Cruz Roja, Universidad de Sevilla, 41004 Sevilla, Spain
38
Digestive Service, Althaia Xarxa Assistencial Universitària de Manresa and Universitat de Vic-Universitat Central de Catalunya (UVicUCC), 08242 Manresa, Spain
39
Laboratoire de Bactériologie, Hôpital Pellegrin, Bordeaux & INSERM U1053 BaRITOn, Université de Bordeaux, 33076 Bordeaux, France
40
Department of Clinical Medicine, Trinity College Dublin, D24 NR0A Dublin, Ireland
*
Author to whom correspondence should be addressed.
Antibiotics 2021, 10(1), 13; https://doi.org/10.3390/antibiotics10010013
Received: 1 December 2020 / Revised: 18 December 2020 / Accepted: 21 December 2020 / Published: 25 December 2020
(This article belongs to the Special Issue Helicobacter pylori: Antibiotic Resistance and Treatment)
The management of Helicobacter pylori infection has to rely on previous local effectiveness due to the geographical variability of antibiotic resistance. The aim of this study was to evaluate the effectiveness of first and second-line H. pylori treatment in Spain, where the empirical prescription is recommended. A multicentre prospective non-interventional registry of the clinical practice of European gastroenterologists concerning H. pylori infection (Hp-EuReg) was developed, including patients from 2013 until June 2019. Effectiveness was evaluated descriptively and through a multivariate analysis concerning age, gender, presence of ulcer, proton-pump inhibitor (PPI) dose, therapy duration and compliance. Overall, 53 Spanish hospitals were included, and 10,267 patients received a first-line therapy. The best results were obtained with the 10-day bismuth single-capsule therapy (95% cure rate by intention-to-treat) and with both the 14-day bismuth-clarithromycin quadruple (PPI-bismuth-clarithromycin-amoxicillin, 91%) and the 14-day non-bismuth quadruple concomitant (PPI-clarithromycin-amoxicillin-metronidazole, 92%) therapies. Second-line therapies were prescribed to 2448 patients, with most-effective therapies being the triple quinolone (PPI-amoxicillin-levofloxacin/moxifloxacin) and the bismuth-levofloxacin quadruple schemes (PPI-bismuth-levofloxacin-amoxicillin) prescribed for 14 days (92%, 89% and 90% effectiveness, respectively), and the bismuth single-capsule (10 days, 88.5%). Compliance, longer duration and higher acid inhibition were associated with higher effectiveness. “Optimized” H. pylori therapies achieve over 90% success in Spain. View Full-Text
Keywords: Helicobacter pylori; treatment; first-line; second-line; Spain Helicobacter pylori; treatment; first-line; second-line; Spain
Show Figures

Figure 1

MDPI and ACS Style

Caldas, M.; Pérez-Aisa, Á.; Castro-Fernández, M.; Bujanda, L.; Lucendo, A.J.; Rodrigo, L.; Huguet, J.M.; Pérez-Lasala, J.; Molina-Infante, J.; Barrio, J.; Fernández-Salazar, L.; Lanas, Á.; Perona, M.; Domínguez-Cajal, M.; Ortuño, J.; Gómez-Rodríguez, B.J.; Almela, P.; Botargués, J.M.; Núñez, Ó.; Modolell, I.; Gómez, J.; Ruiz-Zorrilla, R.; De la Coba, C.; Huerta, A.; Iyo, E.; Pozzati, L.; Antón, R.; Barenys, M.; Angueira, T.; Fernández-Bermejo, M.; Campillo, A.; Alcedo, J.; Pajares-Villaroya, R.; Mego, M.; Bermejo, F.; Dominguez-Jiménez, J.L.; Titó, L.; Fernández, N.; Pabón-Carrasco, M.; Cosme, Á.; Mata-Romero, P.; Alcaide, N.; Ariño, I.; Di Maira, T.; Garre, A.; Puig, I.; Nyssen, O.P.; Megraud, F.; O’Morain, C.; Gisbert, J.P., on behalf of the Hp-EuReg Investigators. European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain. Antibiotics 2021, 10, 13. https://doi.org/10.3390/antibiotics10010013

AMA Style

Caldas M, Pérez-Aisa Á, Castro-Fernández M, Bujanda L, Lucendo AJ, Rodrigo L, Huguet JM, Pérez-Lasala J, Molina-Infante J, Barrio J, Fernández-Salazar L, Lanas Á, Perona M, Domínguez-Cajal M, Ortuño J, Gómez-Rodríguez BJ, Almela P, Botargués JM, Núñez Ó, Modolell I, Gómez J, Ruiz-Zorrilla R, De la Coba C, Huerta A, Iyo E, Pozzati L, Antón R, Barenys M, Angueira T, Fernández-Bermejo M, Campillo A, Alcedo J, Pajares-Villaroya R, Mego M, Bermejo F, Dominguez-Jiménez JL, Titó L, Fernández N, Pabón-Carrasco M, Cosme Á, Mata-Romero P, Alcaide N, Ariño I, Di Maira T, Garre A, Puig I, Nyssen OP, Megraud F, O’Morain C, Gisbert JP on behalf of the Hp-EuReg Investigators. European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain. Antibiotics. 2021; 10(1):13. https://doi.org/10.3390/antibiotics10010013

Chicago/Turabian Style

Caldas, María, Ángeles Pérez-Aisa, Manuel Castro-Fernández, Luis Bujanda, Alfredo J. Lucendo, Luis Rodrigo, Jose M. Huguet, Jorge Pérez-Lasala, Javier Molina-Infante, Jesús Barrio, Luis Fernández-Salazar, Ángel Lanas, Mónica Perona, Manuel Domínguez-Cajal, Juan Ortuño, Blas J. Gómez-Rodríguez, Pedro Almela, Josep M. Botargués, Óscar Núñez, Inés Modolell, Judith Gómez, Rafael Ruiz-Zorrilla, Cristóbal De la Coba, Alain Huerta, Eduardo Iyo, Liliana Pozzati, Rosario Antón, Mercé Barenys, Teresa Angueira, Miguel Fernández-Bermejo, Ana Campillo, Javier Alcedo, Ramón Pajares-Villaroya, Marianela Mego, Fernando Bermejo, José L. Dominguez-Jiménez, Llúcia Titó, Nuria Fernández, Manuel Pabón-Carrasco, Ángel Cosme, Pilar Mata-Romero, Noelia Alcaide, Inés Ariño, Tommaso Di Maira, Ana Garre, Ignasi Puig, Olga P. Nyssen, Francis Megraud, Colm O’Morain, and Javier P. Gisbert on behalf of the Hp-EuReg Investigators 2021. "European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain" Antibiotics 10, no. 1: 13. https://doi.org/10.3390/antibiotics10010013

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop